Marksans Pharma Ltd (MARKSANS) is currently trading at 315.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Marksans Pharma Limited is an integrated pharmaceutical company focused on research, manufacturing and global distribution of formulation products, with a dominant OTC/store-brand presence in the US and a strong front-end in the UK and Australia; the company operates four manufacturing units, four R&D centres and holds multiple accreditations including USFDA, MHRA, TGA and Health Canada. In Q3 FY26 Marksans reported operating revenue of ₹754.4 crore, a 10.6% YoY increase, EBITDA of ₹160.7 crore with a 21.3% margin, and 9M FY26 cash generation of ₹263.2 crore alongside a cash balance of ₹824.2 crore as of December 31, 2025, reflecting improved margins driven by raw material softness, FX tailwinds and operating leverage. Strategically, Marksans is actively expanding its regulated-market footprint: in Q3 FY26 it incorporated subsidiaries in Europe and Canada, continues to pursue Europe-focused M&A, and targets to double US store-brand OTC revenue while aiming for a revenue milestone of ₹3,000 crore and a medium-term INR 4,000 crore target within two to three years. Manufacturing and pipeline scale are core strengths: the firm reports aggregate manufacturing capacity of 26 billion units per annum, plans to double Indian low-cost capacity from 8bn to 16bn units, invested ₹62 crore in R&D in 9M FY26 (3% of revenue), and maintains a pipeline of 100+ products with 300+ ANDAs/MAs approved and 1,500+ SKUs across markets. Marksans combines a cash-positive balance sheet with disciplined capital allocation — including prior ₹372.4 crore equity from warrant conversion in 2023 — and a strong credit profile (CARE AA- / A1+), positioning the company to fund inorganic growth, scale manufacturing and pursue targeted product approvals in regulated markets.

Over the past 52 weeks, Marksans Pharma Ltd has traded between a low of ₹156.00 and a high of ₹349.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Marksans Pharma Ltd has a market capitalization of approximately 14,877.37. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Marksans Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.54 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 14,877.37 Cr, Marksans Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Marksans Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Marksans Pharma Ltd is 28.54. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Operating revenue was ₹840.8 crore in Q1 FY27, up 35.6% year-on-year from ₹620.0 crore.

The most significant announcement is the 'Biopharma Shakti' scheme, a ₹10,000 crore initiative aimed at making India a global biopharmaceutical manufacturing hub, which will strengthen the entire industry ecosystem.